Management of cancer pain: ESMO Clinical Practice Guidelines

Ripamonti, Carla; Santini, Daniele; Maranzano, Ernesto; Berti, Marco; Roila, Fausto

doi:10.1093/annonc/mds233

Cited by 374 publications

(294 citation statements)

References 99 publications

Supporting

Mentioning

262

Contrasting

Unclassified

Order By: Relevance

“…Non-opioid drugs (paracetamol) and mild opioids (codeine, tramadol, and dihydrocodeine) may be useful for mild to moderate pain if administered on a regular basis [166] . Nonsteroidal ant-inflammatory drugs, which can cause renal derangement, should be avoided.…”

Section: Terminal Stagementioning

confidence: 99%

Current management of hepatocellular carcinoma: An Eastern perspective

Yim¹

2015

WJG

View full text Add to dashboard Cite

show abstract

Section: Terminal Stagementioning

confidence: 99%

Current management of hepatocellular carcinoma: An Eastern perspective

Yim¹

2015

WJG

View full text Add to dashboard Cite

show abstract

“…At the second step, a mild, weak-moderate effect opioid such as codeine is selected to supplement the first step. If pain persists, patient progresses to the third step, the weak-effect opioid is replaced by a potent opioid such as morphine, and it is titrated up to pain reducing dose (Ripamonti and Bandieri, 2011). Pharmacological analgesics used in the ladder system are shown in Table 1.…”

Section: Who Guideline For Steps and Pharmacological Treatmentmentioning

confidence: 99%

“…Paracetamol and Non-steroidal anti-inflammatory drugs (NSAIDs) may be used commonly at any stage of cancer pain as a part of the treatment according to WHO's analgesic ladder treatment. Non-opioid analgesics selected and their characteristics are included in Table 2 (Ripamonti and Bandieri., 2011).…”

Section: Who Guideline For Steps and Pharmacological Treatmentmentioning

confidence: 99%

“…Additionally in non-controlled studies, it has been demonstrated that patient progressed to the third step in a short time such as 30-40 days due to basic reasons such as the effect duration of 2 nd step, side effects, and insufficient analgesia. Another limitation in use of weak opioids is the observation of "ceiling effect'' (Ceiling effect is that the effect does not increase although the drug dose increases, and that only side effects are observed additionally) (Ripamonti and Bandieri., 2011).…”

Section: Who Guideline For Steps and Pharmacological Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Cancer Pain Prevalence and its Management

Arslan¹,

Koca²,

Akar³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Pain is a public health problem affecting more than half of cancer patients. Despite the success of the protocols currently used, pain cannot still be reduced satisfactorily in the large majority of patients. In order to improve pain management, all healthcare professionals involved with pain should have sufficient knowledge on pain assessment and treatment, and should inform patients to prevent patient-related barriers. In this compilation, the prevalence values and the treatment methods of cancer pain, and the barriers to pain management have been assessed.

show abstract

“…3 Te WHO is one of many organizations that agree that efective pain control at the end of life may require round-the-clock opioid dosing with additional short-acting opioid for breakthrough pain. 4,5 Opioid therapy is a necessary component of pain control at the end of life, but primary medical teams often shy away from it. 6 Te involvement of a palliative medicine specialist can change this.…”

Section: Opioid Treatment In Palliative Medicine: Unmet Needsmentioning

confidence: 99%

Opioid risk assessment in palliative medicine

Dale

Edwards

Ballantyne

2016

J Community Support Oncol

View full text Add to dashboard Cite

Pain management with opioids is an integral part of palliative medicine. As the doses and durations of opioid therapy increase, the inherent risks of opioid therapy rise. Although opioids are effective analgesics, they bring with them complex medical and psychological side effects. Aberrant behavior is dangerous and can be diffcult to identify as it results in a splitting in the goals of treatment between the patient and providers. One effective strategy in preventing that situation is through the early identifcation of at-risk patients. There are several tools that can help identify patients at higher risk of addiction and aberrant behaviors during opioid therapy. Structured use of these tools in conjunction with the clinic exam, regular follow-up visits, and lab testing can further reduce patient risk and improve success in opioid therapy. This article will review the background behind a structured strategy for opioid risk assessment using the Opioid Risk Tool, SOAPP-R, and DIRE tools. In addition, example aberrant behaviors and followup strategies will be reviewed. It will be demonstrated that careful screening and follow-up allow risk factors to be recognized and addressed early.

show abstract

Management of cancer pain: ESMO Clinical Practice Guidelines

Cited by 374 publications

References 99 publications

Current management of hepatocellular carcinoma: An Eastern perspective

Current management of hepatocellular carcinoma: An Eastern perspective

Cancer Pain Prevalence and its Management

Opioid risk assessment in palliative medicine

Contact Info

Product

Resources

About